Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
October 11, 2017
Sierra Oncology to Present at the 2017 BIO Investor Forum
VANCOUVER, Oct 11, 2017 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) ...
October 11, 2017
BioTime and Processa Announce Their Intention to Enter into a HyStem® Sublicense for Drug Delivery
ALAMEDA, Calif. -- (BUSINESS WIRE) -- BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, ...
October 11, 2017
Marathon Asset Management and ADMA Biologics Complete $30 Million Debt Refinancing
RAMSEY, N.J., Oct. 11, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures ...
October 11, 2017
Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Hyperphagia in Prader-Willi Syndrome
REDWOOD CITY, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare ...
October 11, 2017
Ohr Pharmaceutical to Present at the Dawson James 3rd Annual Small Cap Growth Conference
NEW YORK, Oct. 11, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that ...
October 11, 2017
VBI Vaccines to Present at The World Vaccine Congress Europe 2017 in Barcelona
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Oct 11, 2017) - VBI Vaccines Inc. (VBIV)(VBV.TO) (VBI) today announced that Adam Buckley, vice president of business development, will discuss VBI's ...
October 11, 2017
BioTime Announces First Patient in U.S. Clinical Trial Treated for Facial Volume Deficit
ALAMEDA, Calif.--  (BUSINESS WIRE) -- BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today ...
October 10, 2017
Aradigm Regains Compliance with NASDAQ Listing Requirements
HAYWARD, Calif. -- (BUSINESS WIRE) -- Aradigm Corporation (ARDM) (“Aradigm" or the “Company”) today announced that it received notice from The NASDAQ Capital Market (“NASDAQ”) indicating ...
October 10, 2017
CytoSorbents to Present at the 2017 BIO Investor Forum
MONMOUTH JUNCTION, N.J., Oct. 10, 2017 /PRNewswire/ -- CytoSorbents Corporation(CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in critically ...
October 10, 2017
Rexahn Pharmaceuticals Receives Positive Opinion from European Medicines Agency for Orphan Drug Designation for RX-3117
ROCKVILLE, Md., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE AMERICAN:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment ...
October 10, 2017
Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting®
PASADENA, Calif. -- (BUSINESS WIRE) -- Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it will present preclinical data on ARO-AAT, a second generation investigational medicine for ...
October 9, 2017
CymaBay Announces Oral Late-Breaking Presentation of Interim Results from an Ongoing Phase 2 Study of Patients with Primary Biliary Cholangitis at the AASLD 2017 Liver Meeting
NEWARK, Calif., Oct. 09, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), today announced that a late-breaking presentation describing results from a pre-planned interim analysis ...
October 8, 2017
BioDelivery Sciences Participates in U.S. Department of Health and Human Services Round Table Discussion on Pain Management and Opioid Dependence
RALEIGH, N.C., Oct. 6, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) participated in a round table meeting convened this week in Washington, D.C. by the U.S. Department of Health ...
October 8, 2017
Consistent Efficacy and Safety Profile Observed in New Analyses of OASIS-1 Phase 3 Study of Omadacycline in Patients with Difficult to Treat Comorbid Conditions
SAN DIEGO, Oct. 06, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals (PRTK) announced the results of three sub-analyses from the Phase 3 OASIS-1 study that show ...
October 8, 2017
Phase 3 Optic Study Microbiology Data Demonstrate Omadacycline has Potent In vitro Activity Against Multiple Pneumonia Pathogens, Including Resistant Bacteria
SAN DIEGO, Oct. 06, 2017 (GLOBE NEWSWIRE) -- New microbiology data from Paratek Pharmaceuticals (PRTK) show that its well-tolerated, once-daily, oral and IV, broad-spectrum investigational ...
October 8, 2017
Kitov Boosts Ownership in TyrNovo and Oncology Platform Through Exchange of Shares for Stock
TEL AVIV, Israel, Oct. 6, 2017 /PRNewswire/ -- Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), ("Kitov" or "the Company") an innovative biopharmaceutical company, announced today the ...
October 8, 2017
Spring Bank Pharmaceuticals Announces Two Presentations at the 2017 AASLD Conference in Washington, D.C.
HOPKINTON, Mass., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
October 3, 2017
Zogenix Prices Public Offering of Common Stock
EMERYVILLE, Calif., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system ...
October 3, 2017
Santhera Presents Data and Hosts Symposium on Respiratory Function Decline in Duchenne Muscular Dystrophy at the World Muscle Society Congress
Liestal, Switzerland, October 3, 2017 - Santhera Pharmaceuticals (SIX: SANN) announces that it will present additional data from the positive Phase III DELOS trial in patients with ...
October 3, 2017
AC Immune Awarded Continuation of 2015 Grant from The Michael J. Fox Foundation for Parkinson's Research
Lausanne, Switzerland, - October 3, 2017 -   AC Immune SA (ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, ...
Page 133 of 162